Vistagen Therapeutics, Inc. - Common Stock (VTGN) - InvestorPlace

Aug 13, 2024 · VTGN Stock Predictions, Articles, and Vistagen Therapeutics, Inc. - Common Stock News Meme Stock Rebound: 3 Reddit Favorites Primed for a Resurgence By Viktor …

650%
OFF

Why Is Vistagen Therapeutics (VTGN) Stock Up 650% Today?

2 weeks from now

Aug 7, 2023 · Vistagen Therapeutics (NASDAQ: VTGN) stock is surging to impressive levels today on news of some positive trial results.The pharmaceutical producer has been struggling …

investorplace.com

$3.34
OFF

Vistagen Therapeutics | VTGN Stock Price, Company Overview

2 weeks from now

Vistagen Therapeutics. VTGN. $3.34 ... as of January 3 4:00:00 PM EST. Vistagen Therapeutics (VTGN) Stock Price Performance. Vistagen Therapeutics (VTGN) Stock Key Data. Summary …

forbes.com

43%
OFF

VistaGen Therapeutics (VTGN) P/E Ratio - Public.com

2 weeks from now

2 days ago · The P/E ratio for VistaGen Therapeutics (VTGN) is -2.12 as of Jan 14, 2025.This represents a increase of 4.43% compared to its 12-month average P/E ratio of-2.03.A higher …

public.com

$2.97
OFF

Vistagen Therapeutics (VTGN) Earnings Date And Reports 2025

2 weeks from now

→ This Crypto Is Set to Explode in January (From Crypto 101 Media) (Ad) Free VTGN Stock Alerts. Vistagen Therapeutics (VTGN) Earnings Date, Estimates & Call Transcripts $2.97 …

marketbeat.com

FAQs about Vistagen Therapeutics, Inc. - Common Stock (VTGN) - InvestorPlace Coupon?

Where is VistaGen Therapeutics (vtgn) headquartered?

The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA. View Vistagen Therapeutics, Inc. VTGN stock quote prices, financial information, real-time forecasts, and company news from CNN. ...

Should you buy VistaGen Therapeutics (vtgn) stock?

O’Brient loves helping everyone understand the complexities of economics. He is ranked in the top 15% of stock pickers on TipRanks. Vistagen Therapeutics has reported positive Phase 3 trial results for a social anxiety treatment. VTGN stock is skyrocketing as a result. ...

Why is VistaGen Therapeutics stock falling?

VistaGen Therapeutics (NASDAQ: VTGN) stock is falling hard on Friday after the clinical-stage biopharmaceutical company reported poor results from a Phase 3 study. That clinical trial covers PH94B as a treatment for anxiety in adults with social anxiety disorder. The bad news is that PH94B failed to meet the primary endpoint of the clinical trial. ...

What does vtgn stand for?

Find the latest Vistagen Therapeutics, Inc. (VTGN) stock quote, history, news and other vital information to help you with your stock trading and investing. ...

How much did VistaGen Therapeutics (vtgn) earn in a quarter?

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.06. The business earned $0.08 million during the quarter, compared to analysts' expectations of $0.30 million. ...

Why is VistaGen Therapeutics (vtgn) stock diving lower?

VistaGen Therapeutics ( VTGN) stock is diving lower on poor results from a clinical trial. This saw a Phase 3 study of PH94B fail to meet its primary endpoint. This has heavy trading dragging the company’s shares lower today. ...